{"schema_version":"secwatch.filing_event.v1","accession":"0001321732-25-000010","form_type":"8-K","ticker":"PEN","cik":"0001321732","company_name":"Penumbra Inc","filed_at":"2025-02-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.286596+00:00","generated_at":"2026-05-26T14:46:36.902649+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Penumbra Q4 adjusted revenue $321.3M (+13%); U.S. thrombectomy up 27%","bullets":["Adjusted revenue (excl. Italian payback) Q4 $321.3M, up 12.9% YoY; reported revenue $315.5M (+10.8%).","GAAP net income Q4 $33.7M (10.7% margin); full-year net income $14.0M.","Adjusted EBITDA Q4 $63.7M (19.8% margin); full-year $171.0M (14.2% margin).","U.S. thrombectomy products grew 27.3% in Q4; international thrombectomy revenue declined 13.9% adjusted.","Full-year adjusted revenue $1,200.4M, up 13.4% YoY."],"urls":{"canonical":"https://secwatch.observer/filing/0001321732-25-000010","json":"https://secwatch.observer/filing/0001321732-25-000010.json","markdown":"https://secwatch.observer/filing/0001321732-25-000010.md","text":"https://secwatch.observer/filing/0001321732-25-000010.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1321732/000132173225000010/0001321732-25-000010-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1321732/000132173225000010/pen-20250218.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T14:46:36.902649+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}